# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Rodman & Renshaw analyst Elemer Piros reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $67 price target.
Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson'...
This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1), which has dem...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $23 price tar...
Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage drug platform company developing novel ...